Study Name Principal Investigator
(MK7339-002) A Phase 2 Study of Olaparib Monotherapy in Participants with Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer Nayak-Kapoor, Asha
1951-CL-0101 A Phase 1b Study of ASP1951, a GITR Agonistic Antibody, as a Single Agent and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors Ghamande, Sharad
A Phase 1 / 2, Open-Label, Multiple Ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of AGEN2034 in Subjects With Metastatic or Locally Advanced Solid Tumors, With Expansion to Second-Line Cervical Cancer Ghamande, Sharad
A PHASE 1/2A, MULTICENTER, OPEN-LABEL STUDY OF LYC-55716 IN ADULT SUBJECTS WITH LOCALLY ADVANCED OR METASTATIC CANCER Ghamande, Sharad
ALKS 4230-001: A Phase 1/2 Study of ALKS 4230 Administered Subcutaneously as Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors- ARTISTRY-2 (001) Nayak-Kapoor, Asha
Biomarkers and Therapies for Cancer (BAT Cancer) McIndoe, Richard
CDX1140-01: A Phase 1 Study of CDX-1140, a Fully Human Agonist anti-CD40 Monoclonal Antibody, as Monotherapy or in Combination in Patients with Advanced Malignancies Kota, Vamsi
D081RC00001 A Phase III Randomised, Double-Blind, Placebo-Controlled, Multicentre Study of Durvalumab in Combination with Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib in Newly Diagnosed Advanced Ovarian Cancer Patients (DUO-O) Ghamande, Sharad
EP0057-201: A Phase 2 study to evaluate the safety and efficacy of EP0057 in combination with Olaparib in advanced ovarian cancer patients who have: Cohort 1 – platinum resistant disease and are PARP inhibitor naïve; Cohort 2 – had at least 2 prior lines of therapy which must include at least 1 line of platinum-based chemotherapy followed by PARP. Ghamande, Sharad
FPA150-001: A Phase 1a/1b Study of FPA150, an Anti-B7-H4 Antibody, in Patients with Advanced Solid Tumors Ghamande, Sharad
MER-XMT-1536-1/GOG 3048: A Phase 1b/2, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients with Solid Tumors Likely to Express NaPi2b Ghamande, Sharad
MORAb-202-G000-201: A Multicenter, Open-Label Phase 1/2 Trial Evaluating the Safety, Tolerability, and Efficacy of MORAb-202, a folate receptor alpha (FR?)-targeting antibody-drug conjugate (ADC) in Subjects With Selected Tumor Types Ghamande, Sharad
NKTR 16-214-05 (PROPEL) - A PHASE 1/2, OPEN-LABEL, MULTICENTER STUDY TO INVESTIGATE THE SAFETY AND PRELIMINARY EFFICACY OF COMBINED BEMPEGALDESLEUKIN (NKTR-214) AND PEMBROLIZUMAB WITH OR WITHOUT CHEMOTHERAPY IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS Raval, Girindra
PRT543-01: A Phase I, Open-Label, Multicenter, Dose Escalation, Dose Expansion Study of PRT543 in Patients with Advanced Solid Tumors and Hematologic Malignancies Cortes, Jorge
PRT811-01: A Phase 1, Open-Label, Multicenter, Dose Escalation and Expansion Study of PRT811 in Subjects with Advanced Solid Tumors and Recurrent High-Grade Gliomas Henson, John
TAEK-VAC-HerBy-001: Phase 1 trial of intravenous administration of TAEK-VAC-HerBy vaccine alone and in combination with HER2-antibodies in patients with advanced cancer Raval, Priyanka
TESARO 4010-01-001: A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an anti-PD-1 Monoclonal Antibody, in Patients with Advanced Solid Tumors Ghamande, Sharad
Translational Research in Benign and Malignant Genitourinary, Gastrointestinal, and Breast Diseases. Lokeshwar, Vinata
TRX518-004: A Dose Escalation and Expansion Study of TRX518 in Combination with Cyclophosphamide Plus Avelumab in Advanced Solid Tumors Nayak-Kapoor, Asha
RESEARCH. INNOVATION. DISCOVERY.
Augusta University
Research
AU Health
Stay Informed
Get updates on new trials and more
(706)721-6582 © Augusta University 1120 15th Street Augusta, GA 30912